Gen İlaç has taken a significant step by increasing its ownership stake in Elixir A.Ş. to 95%.
# Ownership Stake Increased to 95%
Gen İlaç and Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GENIL) announced via the Public Disclosure Platform (KAP) that it has increased its ownership stake in Elixir İlaç Araştırma ve Geliştirme A.Ş. The company purchased a 10% share of Elixir, raising its total ownership stake to 95%.
# Strategic Move by Gen İlaç
Gen İlaç will pay 8,950,000.00 TL for Elixir’s 10% share. With this transaction, Fırat Yerlikaya’s shareholding in Elixir has ended. This move by Gen İlaç aims to strengthen its position in the pharmaceutical research and development sector.
Gen İlaç’s increase of its ownership stake in Elixir A.Ş. to 95% provides significant insights into the company’s future plans.
Source
Arwen Volkov, A graduate of the University of St. Gallen in Switzerland with a degree in International Finance, Arwen specializes in sustainable finance and green investments. She began her career at an investment bank in London, where she developed financing models for environmentally friendly projects. Known for her analytical and strategic thinking skills, Arwen is a sought-after financial consultant. In her spare time, she mentors fintech startups, contributing to their growth strategies. She is also a nature enthusiast and an amateur photographer.
